Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ETON vs AYTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ETON Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

ETON Overall Winner 6-Pillar Tally: ETON 4 – 2 AYTU Matrix Metrics: ETON 6 – 4 AYTU

As of Nov 16, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ETON carries a Unified Composite Score of 36.5/100 (SELL) at $64.30 (19.3x Forward P/E, 31.3% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin).

  • Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ETON 36.5/100 SELL), ETON captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -14.4% operating margin) and revenue trajectory (+157.9% vs. +6.4% YoY).
  • Technical & Structure Timing Caution: ETON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.3); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ETON vs AYTU
ETON NASDAQ Head-to-Head Winner
Eton Pharmaceutcials, Inc. Common Stock
Pharmaceutical Preparations
$64.30
+0.58% 1D
Market Cap $1.8B
TTM Revenue $141M
Forward P/E 19.3x
Beta / 30D Vol 0.63β · 99% Vol
Unified Composite Score
36.5 / 100 SELL
Tech 50.0 Fund 36.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 62.3 · SMA20: $55.23 · SMA50: $55.38
AYTU NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00

6-Pillar Scorecard Institutional Category Breakdown (ETON 4 – 2 AYTU)

Columns: Metric · ETON · AYTU
1. Valuation Multiples AYTU
Forward P/E 19.3x 9.2x
Trailing P/E 39.9x 9.2x
PEG Ratio N/M N/M
EV / Revenue 12.3x 0.3x
2. Growth & Scale ETON
Revenue Growth (YoY) +157.9% +6.4%
Earnings Growth (YoY) -12.6% +0.0%
TTM Revenue (USD) $141M $58M
Market Cap $1.8B $19.6M
3. Profitability & Quality ETON
Gross Margin 71.2% 64.0%
Operating Margin 31.3% -14.4%
Net Profit Margin 35.4% -24.8%
Return on Equity (ROE) 90.6% -52.5%
4. Balance Sheet & Cash Flow ETON
Cash Generation (TTM) $20M -$1.4M
Cash Flow Margin 14.2% -2.4%
Net Cash / Leverage $32M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ETON
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 59.3% (14th %ile) N/A (N/A)
Put/Call OI Skew 0.13x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 39.9% of Rev ($56M) 78.4% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ETON (6) vs AYTU (4)
Institutional Metric ETON AYTU Criterion Row Edge
Market Capitalization
Scale
$1.8B $19.6M Larger Scale ETON
Trailing P/E Ratio
Valuation
39.9x 9.2x Lower Multiple AYTU
Forward P/E Ratio
Valuation
19.3x 9.2x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+157.9% +6.4% Higher Growth ETON
Operating Margin (TTM)
Profitability
31.3% -14.4% Higher Margin ETON
Net Profit Margin
Profitability
35.4% -24.8% Higher Margin ETON
Return on Equity (ROE)
Capital Efficiency
90.6% -52.5% Higher ROE ETON
52-Week Range Position
Momentum
89% ($14–$71) 5% ($2–$3) Stronger Trend ETON
Beta / 30D Volatility
Risk Regime
0.63β · 99% Vol 0.65β · 35% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
36.5 / 100 (SELL) 48.9 / 100 (HOLD) Higher Composite AYTU
Trailing 12M Revenue (USD)
Operating Scale
$141M $58M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.2% 64.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 12.3x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($32M Net Cash) -$1.4M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ETON +39.08 pp
ETON: +27.81% · AYTU: -11.27%
3M Horizon ETON +24.68 pp
ETON: +1.37% · AYTU: -23.31%
6M Horizon ETON +111.72 pp
ETON: +97.91% · AYTU: -13.81%
1Y Horizon ETON +293.06 pp
ETON: +280.92% · AYTU: -12.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ETON Revenue AYTU Revenue ETON Op. Margin AYTU Op. Margin Margin Leader
FY2019 $0M $10M -1939.6% -230.1% AYTU
FY2020 $0M $30M -69515.4% -76.5% AYTU
FY2021 $20M $70M -6.8% -89.7% ETON
FY2022 $20M $100M -38.9% -113.7% ETON
FY2023 $30M $110M -3.8% -15.9% ETON
FY2024 $40M $70M -6.7% -2.4% AYTU
FY2025 $80M $70M -1.1% -11.8% ETON
FY2026 N/A $60M N/A -14.4% AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ETON CONSOLIDATION
59d in phase · OBV ACCUMULATION
Current IV 59.3%
IV Percentile 14th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ETON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ETON Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.8B market capitalization and 31.3% operating margin.
OpEx & R&D Reinvestment 39.9% of Rev ($56M)
90D Engineering Disclosures 0 Published
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ ETON vs AYTU Key Questions & Quantitative Answers

As of Nov 16, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ETON carries a Unified Composite Score of 36.5/100 (SELL) at $64.30 (19.3x Forward P/E, 31.3% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin). Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ETON 36.5/100 SELL), ETON captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -14.4% operating margin) and revenue trajectory (+157.9% vs. +6.4% YoY). Technical & Structure Timing Caution: ETON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.3); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ETON leads the Growth & Scale pillar: ETON posts +157.9% YoY revenue growth and -12.6% YoY earnings growth on $141M TTM revenue (71.2% gross margin, 31.3% operating margin), compared with AYTU at +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), ETON cumulative revenue shifted +300.0% while AYTU shifted +500.0%. In operating R&D and SG&A reinvestment, ETON deploys 39.9% of Rev ($56M) (0 90-day corporate R&D disclosures) versus 78.4% of Rev ($45M) (0 disclosures) for AYTU.

AYTU screens cheaper on headline valuation multiples. ETON trades at 19.3x Forward P/E, 39.9x Trailing P/E, N/M PEG, and 12.3x EV/Revenue (14.2% FCF margin), whereas AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ETON (90.6% ROE) versus AYTU (-52.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ETON carries 59.3% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.63β · 99% Vol realized risk). By comparison, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.